A broth dilution checkerboard synergy assay was used to assess the activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, in combination with tobramycin, against 38 strains of Pseudomonas aeruginosa. Synergy occurred significantly more often (P < 0;001) when tobramycin was combined with cefotaxime (63%) than when it was combined with carbenicillin (26%), cefoperazone (21%), or moxalactam (18%). Of the 25 synergistically inhibited strains, the combination cefotaxime-tobramycin was synergistic against 24 and was the only synergistic combination against 10. Of six strains initially resistant to cefotaxime, five were susceptible to this agent (minimum inhibitory concentration, -32 ,ug/ ml) when it was combined with tobramycin. Clinical trials are needed to determine the therapeutic efficacy of cefotaxime-aminoglycoside combinations in the treatment of serious Pseudomonas infections. 
Antibiotic combinations are widely employed in the treatment of serious Pseudomonas aeruginosa infections, particularly in leukopenic or immunosuppressed patients. Empiric regimens traditionally combine an aminoglycoside with an antipseudomonal fi-lactam antibiotic such as carbenicillin or ticarcillin to achieve additive or synergistic antibacterial activity (5, 11, 12) . Although the clinical relevance of in vitro synergy has not been fully defined (8, 11) , a number of studies with experimental animals (1, 2, 13) and with humans (6, 7) indicate that Pseudomonas infections respond more favorably to synergistic than to nonsynergistic antibiotic combinations. In addition, by lowering antibiotic minimal inhibitory concentrations (MICs), synergistic combinations permit therapeutically achievable aminoglycoside levels to exceed more effectively the MIC of the infecting Pseudomonas.
Cefoperazone domonas, the combination tobramycin-cefotax. ime was synergistic against 24 and was the sole synergistic combination against 10 strains. Tobramycin plus cefoperazone was the sole synergistic combination against one isolate.
The resistance breakpoints for tobramycin and carbenicillin were >4 ,ug/ml and >128 ,Lg/ ml, respectively. Resistance breakpoints for the newer 8)-lactam agents have not been defined, although resistance to cefotaxime has recently been proposed as >32 ,ug/ml (4). If a similar level is assumed for cefoperazone and moxalactam, then resistance to a ,B-lactam agent was observed in 11 instances (cefotaxime, 6; carbenicillin, 3; moxalactam, 2). However, in eight of these instances synergy was achieved, resulting in a decrease in the MIC of the fl-lactam antibiotic to within the susceptible range (Table 3) . Similarly, the single tobramycin-resistant strain (MIC, 16 ,ug/ml) was susceptible to 4 ,ug of that agent per ml when combined with either carbenicillin or cefotaxime.
DISCUSSION
In this study a stringent definition of synergy (fourfold reduction in MIC of both agents) was applied to the broth dilution checkerboard assay. In a recent comparison of synergy techniques by Norden et al. (10) , this proved to be the most rigorous test system evaluated in that it yielded the fewest positive results. Thus, the results obtained in the present study tend to be a conservative estimate of the synergistic potential of the various antibiotic combinations.
The value of in vitro synergy testing against gram-negative organisms can be established only by determining its relevance to the therapeutic outcome of clinical infections (8) . To this end, studies with neutropenic (13) (6) . Analysis of the results presented here might suggest that the synergistic increase in activity of cefotaxime when combined with tobramycin does little more than lower the MIC of cefotaxime to that of cefoperazone. More important, however, is the fact that this combination resulted in a fourfold lowering of the tobramycin MIC significantly more often than did any other tobramycin-fl-lactam combination (P < 0.001).
This enhancement is of particular importance when treating Pseudomonas infections since the toxic-therapeutic ratio of aminoglycosides is considerably lower for this organism than for other gram-negative bacilli.
These data do not establish the superiority of aminoglycoside-cefotaxime combinations in the treatment of serious Pseudomonas infections. They do, however, suggest the need for in vivo studies to compare the therapeutic efficacy of cefotaxime plus an aminoglycoside with currently available antipseudomonal regimens.
Such studies must also determine whether simultaneous administration of cefotaxime and an aminoglycoside increases the risk of nephrotoxicity, as has been observed with cephalothinaminoglycoside combinations (3, 14) .
